Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ILLUMINA, INC.ILMN · Entity 3137 | SVP Chief Commercial Officer | November 05, 2020 | November 09, 2020 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | See Remarks | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ILLUMINA, INC.
Report date November 05, 2020 · Filed November 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,575 |
Reported balance
After 2020-11-05 transaction · row 1
1 source rowRow 1 · 2020-11-05 · Tax withholding · Disposed 1,073 · Balance 16,575 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,705,853 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 26,911 · Balance 2,705,853 F1: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This sale price represents the weighted average sale price of the shares sold ranging from $1.13 to $1.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This sale price represents the weighted average sale price of the shares sold ranging from $1.13 to $1.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 00:17 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 26,911 | $1.13 | $30,409.43 |
DisclosureSEC source: 0001299130-26-000128 · wk-form4_1787098653.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,705,853 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.13 to $1.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:54 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 1,967,888 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001299130-26-000126 · wk-form4_1786485289.xml · derivative · entry 2 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,967,888 Underlying: Common Stock · 1,967,888 shares Expires 2036-08-10 F2 · derivative.exercise_date: The shares subject to the option will vest in 36 equal monthly installments beginning on September 10, 2026, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:54 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 489,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-26-000126 · wk-form4_1786485289.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,732,764 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on August 10 of each of 2027, 2028, and 2029, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 22:54 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 6,504 | $1.51 | $9,847.06 |
DisclosureSEC source: 0001299130-26-000042 · wk-form4_1772664888.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,243,634 F1 · shares: Represents the number of shares mandatorily sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.49 to $1.56 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 7,500 shares purchased on March 2, 2026 under the Company's 2010 Employee Stock Purchase Plan. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:13 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001299130-26-000038 · wk-form4_1772579582.xml · derivative · entry 2 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2036-02-27 F2 · derivative.exercise_date: The shares subject to the option will vest in 36 equal monthly installments beginning on March 27, 2026, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:13 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-26-000038 · wk-form4_1772579582.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,242,638 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15 of each of 2027, 2028, and 2029, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 01:33 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 55,107 | $1.63 | $89,769.30 |
DisclosureSEC source: 0001299130-26-000023 · wk-form4_1771551212.xml · nonDerivative · entry 2 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,742,638 F1 · shares: Represents the number of shares mandatorily sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F4 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.55 to $1.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 7,500 shares purchased on September 2, 2025 under the Company's 2010 Employee Stock Purchase Plan. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 01:33 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 129,790 | $1.58 | $204,549.04 |
DisclosureSEC source: 0001299130-26-000023 · wk-form4_1771551212.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,797,745 F1 · shares: Represents the number of shares mandatorily sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.51 to $1.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 7,500 shares purchased on September 2, 2025 under the Company's 2010 Employee Stock Purchase Plan. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:06 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 26,836 | $1.31 | $35,182.00 |
DisclosureSEC source: 0001299130-25-000160 · wk-form4_1755720402.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,920,035 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.30 to $1.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 20:54 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 898,352 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001299130-25-000068 · wk-form4_1742590446.xml · derivative · entry 2 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 898,352 Underlying: Common Stock · 898,352 shares Expires 2035-03-19 F2 · derivative.exercise_date: The shares subject to the option will vest in 24 equal monthly installments beginning on March 15, 2025, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 20:54 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 449,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-25-000068 · wk-form4_1742590446.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,946,871 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15 of each of 2026 and 2027, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:37 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 6,486 | $1.41 | $9,125.80 |
DisclosureSEC source: 0001299130-25-000047 · wk-form4_1741210615.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,497,695 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.39 to $1.46 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 7,500 shares purchased on March 3, 2025 under the Company's 2010 Employee Stock Purchase Plan. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:59 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 100,773 | $1.88 | $189,251.69 |
DisclosureSEC source: 0001299130-25-000038 · wk-form4_1740002370.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,496,681 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.80 to $2.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 10, 2025 Filed Jan 10, 2025 21:54 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 34,405 | $2.03 | $69,979.77 |
DisclosureSEC source: 0001299130-25-000006 · wk-form4_1736546044.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,597,454 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.99 to $2.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 1,044 shares purchased on September 3, 2024 under the Company's 2010 Employee Stock Purchase Plan. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 21:25 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 38,011 | $1.66 | $63,174.28 |
DisclosureSEC source: 0001299130-24-000172 · wk-form4_1724189141.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,630,815 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $1.64 to $1.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:26 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 9,186 | $4.87 | $44,745.01 |
DisclosureSEC source: 0001299130-24-000072 · wk-form4_1709763991.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,668,826 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $4.72 to $5.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 3,325 shares purchased on March 1, 2024 under the Company's 2010 Employee Stock Purchase Plan. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 21:55 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 798,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-24-000044 · wk-form4_1708984516.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,674,687 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15th of each of 2025, 2026, 2027, and 2028, provided that the Reporting Person continues to serve through each applicable vesting date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 23:25 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 33,560 | $5.96 | $199,950.48 |
DisclosureSEC source: 0001299130-24-000029 · wk-form4_1708557897.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 876,611 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $5.69 to $6.65 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 22:44 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 31,012 | $7.77 | $241,056.28 |
DisclosureSEC source: 0001299130-24-000008 · wk-form4_1704926655.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 910,171 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $7.54 to $8.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 1,414 shares purchased on September 1, 2023 under the Company's 2010 Employee Stock Purchase Plan. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:26 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 26,102 | $11.00 | $287,122.00 |
DisclosureSEC source: 0001299130-23-000107 · wf-form4_169239035719451.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 939,769 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $10.91 to $11.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 6,268 | $9.49 | $59,502.12 |
DisclosureSEC source: 0001299130-23-000040 · certent-form4.xml · nonDerivative · entry 2 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 965,871 F3 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F4 · price: This sale price represents the weighted average sale price of the shares sold ranging from $9.24 to $9.71 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:50 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 328,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-23-000040 · certent-form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972,139 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15th of each of 2024, 2025, 2026, and 2027, provided that the Reporting Person continues to serve through each applicable vesting date. F2 · balance_after: Includes 2,831 shares purchased on March 1, 2023 under the Company's 2010 Employee Stock Purchase Plan. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 23:29 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 26,722 | $9.53 | $254,767.55 |
DisclosureSEC source: 0001299130-23-000012 · certent-form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,808 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $9.35 to $9.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 2 shares purchased on September 1, 2022 under the Company's 2010 Employee Stock Purchase Plan. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 22:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-22-000108 · certent-form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,528 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on August 15th of each of 2023, 2024, 2025, and 2026, provided that the Reporting Person continues to serve through each vesting date. F2 · balance_after: Includes 1,508 shares purchased on September 1, 2021 and March 1, 2022 under the Company's 2010 Employee Stock Purchase Plan. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 00:23 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 433,200 | $0.00 Strike: $11.70 | $0.00 |
DisclosureSEC source: 0001299130-22-000035 · certent-form4.xml · derivative · entry 2 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,200 Underlying: Common Stock · 433,200 shares Expires 2032-03-02 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the next four years, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| March 02, 2022 Filed Mar 5, 2022 00:23 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 72,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-22-000035 · certent-form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,020 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on March 2 of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 23:15 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | SaleCommon Stock | 41,480 | $14.23 | $590,260.40 |
DisclosureSEC source: 0001299130-22-000012 · certent-form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,520 F1 · shares: Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This sale price represents the weighted average sale price of the shares sold ranging from $14.05 to $14.42 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 23:14 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001299130-21-000024 · certent-form4.xml · derivative · entry 2 Van Oene Mark · CIK 0001707477 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2031-01-08 F2 · derivative.exercise_date: 1/4 of the shares subject to the option will vest on the one year anniversary of the date of grant, and the balance of shares will vest monthly thereafter over the next three years, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 23:14 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 335,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-21-000024 · certent-form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,000 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on January 8 of each of 2022, 2023, 2024, and 2025, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,073 | $311.72 | $334,475.56 |
DisclosureSEC source: 0001127602-20-028507 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,575 Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 23:52 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 40 | $356.39 | $14,255.40 |
DisclosureSEC source: 0001127602-20-024658 · form4.xml · nonDerivative · entry 2 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,648 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F4 · price: Weighted average sale price representing 40 shares sold ranging from $356.29 to $356.48 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 23:52 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 585 | $355.04 | $207,697.76 |
DisclosureSEC source: 0001127602-20-024658 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,688 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 585 shares sold ranging from $354.845 to $355.21 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. F2 · balance_after: Balance includes 18 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 625 | $385.43 | $240,893.75 |
DisclosureSEC source: 0001127602-20-022957 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,255 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 625 shares sold ranging from $385 to $385.56 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:25 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 400 | $370.10 | $148,040.00 |
DisclosureSEC source: 0001127602-20-021172 · form4.xml · nonDerivative · entry 3 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,880 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 400 shares sold ranging from $369.86 to $370.35 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:25 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 100 | $368.74 | $36,874.00 |
DisclosureSEC source: 0001127602-20-021172 · form4.xml · nonDerivative · entry 2 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,280 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:25 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 125 | $367.68 | $45,960.00 |
DisclosureSEC source: 0001127602-20-021172 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,380 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 125 shares sold ranging from $367.49 to $368.44 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:27 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 100 | $362.07 | $36,206.50 |
DisclosureSEC source: 0001127602-20-018721 · form4.xml · nonDerivative · entry 2 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,505 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:27 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 525 | $361.44 | $189,756.00 |
DisclosureSEC source: 0001127602-20-018721 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,605 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 525 shares sold ranging from $361.05 to $361.565 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| May 01, 2020 Filed May 5, 2020 23:01 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 100 | $316.86 | $31,685.60 |
DisclosureSEC source: 0001127602-20-015514 · form4.xml · nonDerivative · entry 2 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,130 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 100 shares sold ranging from $316.82 to $316.86 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| May 01, 2020 Filed May 5, 2020 23:01 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 525 | $316.82 | $166,330.50 |
DisclosureSEC source: 0001127602-20-015514 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,230 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 525 shares sold ranging from $315.27 to $315.715 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 21:37 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,250 | $300.22 | $375,275.00 |
DisclosureSEC source: 0001127602-20-014141 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,755 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 1,250 shares sold ranging from $300.00 to $300.32 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:12 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 3,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005393 · form4.xml · derivative · entry 8 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,431 shares Expires 2019-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on May 22, 2017. F4 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on May 22, 2017. F4 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on May 22, 2017. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:12 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 8,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005393 · form4.xml · derivative · entry 7 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,431 Underlying: Common Stock · 8,210 shares Expires 2019-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 2, 2016. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 2, 2016. F2 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 2, 2016. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:12 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 2,552 | $296.00 | $755,392.00 |
DisclosureSEC source: 0001127602-20-005393 · form4.xml · nonDerivative · entry 6 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,005 Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:12 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 5,609 | $296.00 | $1,660,264.00 |
DisclosureSEC source: 0001127602-20-005393 · form4.xml · nonDerivative · entry 5 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,557 Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:12 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 3,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005393 · form4.xml · nonDerivative · entry 4 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on May 22, 2017. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:12 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005393 · form4.xml · nonDerivative · entry 3 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,735 F3 · shares: Represents additional shares of stock awarded as a result of the Company achieving at least 150% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on May 22, 2017. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:12 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 8,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005393 · form4.xml · nonDerivative · entry 2 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 2, 2016. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:12 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 4,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005393 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,809 F1 · shares: Represents additional shares of stock awarded as a result of the Company achieving at least 150% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 2, 2016. Read SEC document |
| February 05, 2020 Filed Feb 6, 2020 21:23 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 625 | $300.24 | $187,650.00 |
DisclosureSEC source: 0001127602-20-003993 · form4.xml · nonDerivative · entry 1 Van Oene Mark · CIK 0001707477 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,623 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 625 shares sold ranging from $300.00 to $300.51 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. F3 · balance_after: Balance includes 70 shares acquired through Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.